Research Paper Herpes Simplex
Now, a multidisciplinary research team at NYU Langone Health has discovered how the virus evades the immune system—a critical discovery that paves the way for novel therapies to treat and potentially eradicate HSV-1 and other herpes viruses.
Infectious viruses engage in a kind of molecular arms race with the immune system, as both invader and host compete to take the lead.
Participants obtained genital swab specimens twice daily for HSV-2 detection and monitored genital lesions for 28-day periods at baseline and at intervals after the last dose.
“When these viruses come out of latency, they can cause many problems,” adds Dr.Compared with baseline, genital HSV-2 shedding rates immediately after dosing were reduced with GEN-003 (from 13.4% to 6.4% for 30 μg [.)Herpes simplex virus type 2 (HSV-2) is a common sexually transmitted pathogen that often causes recurrent genital lesions.Transmission occurs largely from asymptomatic genital tract virus shedding, making this a key target for a therapeutic HSV vaccine.If all goes well for the host, the immune system eventually overwhelms the virus and eliminates it.But some viruses, including herpes simplex viruses, have evolved a clever tactic to linger on: a hibernation state known as viral latency, which allows viruses to lie dormant in a host’s cells, out of sight of the immune system.
The management of genital herpes currently includes episodic or daily suppressive therapy with nucleoside analogues, which abrogates most recurrences but only partly reduces viral shedding and transmission [1, 2].